Order Article Reprints

Khan S, Marquez-Martinez S, Erkens T, de Wilde A, Costes LMM, Vinken P, De Jonghe S, Roosen W, Talia C, Chamanza R, et al. Intravenous Administration of Ad26.COV2.S Does Not Induce Thrombocytopenia or Thrombotic Events or Affect SARS-CoV-2 Spike Protein Bioavailability in Blood Compared with Intramuscular Vaccination in Rabbits. Vaccines. 2023; 11(12):1792. https://doi.org/10.3390/vaccines11121792

Khan, Selina, Sonia Marquez-Martinez, Tim Erkens, Adriaan de Wilde, Lea M. M. Costes, Petra Vinken, Sandra De Jonghe, Wendy Roosen, Chiara Talia, Ronnie Chamanza, and et al. 2023. "Intravenous Administration of Ad26.COV2.S Does Not Induce Thrombocytopenia or Thrombotic Events or Affect SARS-CoV-2 Spike Protein Bioavailability in Blood Compared with Intramuscular Vaccination in Rabbits" Vaccines 11, no. 12: 1792. https://doi.org/10.3390/vaccines11121792

Khan, S., Marquez-Martinez, S., Erkens, T., de Wilde, A., Costes, L. M. M., Vinken, P., De Jonghe, S., Roosen, W., Talia, C., Chamanza, R., Serroyen, J., Tolboom, J., Zahn, R. C., & Wegmann, F. (2023). Intravenous Administration of Ad26.COV2.S Does Not Induce Thrombocytopenia or Thrombotic Events or Affect SARS-CoV-2 Spike Protein Bioavailability in Blood Compared with Intramuscular Vaccination in Rabbits. Vaccines, 11(12), 1792. https://doi.org/10.3390/vaccines11121792